Karp Natasha A
Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
Commun Biol. 2025 Apr 29;8(1):681. doi: 10.1038/s42003-025-08118-4.
After thirty years of research highlighting the risk of the sex bias in preclinical research, we now have tangible change happening in the research landscape with a rapid increase in the proportions of studies including female and male subjects. In practical terms, this will require a paradigm shift affecting choices around experimental design, analysis and presentation and considerations when drawing conclusions and planning next steps in the pipeline. As the preclinical research community embraces this new way of working, numerous insights are being published and shared on how to proceed. This article will signpost the learnings obtained and potential future steps that should be focused on.
在经过三十年强调临床前研究中性别偏见风险的研究之后,我们现在看到研究领域正在发生切实的变化,纳入雌性和雄性实验对象的研究比例迅速增加。实际上,这将需要一种范式转变,影响围绕实验设计、分析和呈现的选择,以及在得出结论和规划后续步骤时的考量。随着临床前研究界接受这种新的工作方式,关于如何推进的大量见解正在发表和分享。本文将指出所获得的经验教训以及未来应关注的潜在步骤。